Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01615029 · ClinicalTrials.gov registry record · Phase 1
Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT01615029 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 45 participants.
The verdict
NCT01615029, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to establish the safety profile of daratumumab when given in combination with Lenalidomide and dexamethasone in participants with relapsed or relapsed and refractory Multiple Myeloma (MM).
Interventions
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Part 1 (Dose Escalation): Daratumumab
- DRUG Part 2 (Dose Expansion): Daratumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2012-06-26 |
| Est. Completion | 2024-10-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01615029
The ClinicalTrials.gov registry entry for NCT01615029 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dexamethasone is the first listed.
NCT01615029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01615029 about?
NCT01615029 is a clinical study titled "Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma". The purpose of this study is to establish the safety profile of daratumumab when given in combination with Lenalidomide and dexamethasone in participants with relapsed or relapsed and refractory Multiple Myeloma (MM).
What is the current status of trial NCT01615029?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2012-06-26. Estimated completion is 2024-10-23.
What interventions are being tested in trial NCT01615029?
The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Part 1 (Dose Escalation): Daratumumab (DRUG), Part 2 (Dose Expansion): Daratumumab (DRUG).
Who is sponsoring clinical trial NCT01615029?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.